Related Experiment Video
Updated: Apr 5, 2026
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
Published on: October 14, 2016
A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia
George Giotopoulos1, Louise van der Weyden2, Hikari Osaki1
1Department of Haematology, Cambridge Institute for Medical Research and Addenbrooke's Hospital, University of Cambridge, Cambridge CB2 0XY, England, UK Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 1TN, England, UK.
Abstract:
The introduction of highly selective ABL-tyrosine kinase inhibitors (TKIs) has revolutionized therapy for chronic myeloid leukemia (CML). However, TKIs are only efficacious in the chronic phase of the disease and effective therapies for TKI-refractory CML, or after progression to blast crisis (BC), are lacking. Whereas the chronic phase of CML is dependent on BCR-ABL, additional mutations are required for progression to BC. However, the identity of these mutations and the pathways they affect are poorly understood, hampering our ability to identify therapeutic targets and improve outcomes. Here, we describe a novel mouse model that allows identification of mechanisms of BC progression in an unbiased and tractable manner, using transposon-based insertional mutagenesis on the background of chronic phase CML. Our BC model is the first to faithfully recapitulate the phenotype, cellular and molecular biology of human CML progression. We report a heterogeneous and unique pattern of insertions identifying known and novel candidate genes and demonstrate that these pathways drive disease progression and provide potential targets for novel therapeutic strategies. Our model greatly informs the biology of CML progression and provides a potent resource for the development of candidate therapies to improve the dismal outcomes in this highly aggressive disease.
Insights
Researchers developed a new mouse model to study chronic myeloid leukemia (CML) blast crisis (BC). This model identifies genetic mutations driving BC progression, offering new therapeutic targets for this aggressive blood cancer.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Tyrosine kinase inhibitors (TKIs) transformed chronic myeloid leukemia (CML) treatment.
- TKIs are ineffective in CML blast crisis (BC) and TKI-refractory CML.
- Mechanisms driving CML progression to BC are poorly understood.
Purpose of the Study:
- To develop a novel mouse model for unbiased identification of genes and pathways involved in CML blast crisis progression.
- To understand the molecular mechanisms underlying the transition from chronic phase CML to BC.
- To identify potential therapeutic targets for advanced CML.
Main Methods:
- Transposon-based insertional mutagenesis in a mouse model of chronic phase CML.
- Analysis of genetic alterations and their impact on disease progression.
- Phenotypic, cellular, and molecular characterization of the developed BC model.
Main Results:
- A novel mouse model that accurately recapitulates human CML BC was established.
- A heterogeneous pattern of genetic insertions identified known and novel candidate genes driving BC.
- These identified pathways are crucial for disease progression and represent potential therapeutic targets.
Conclusions:
- The developed mouse model provides a powerful tool for studying CML BC biology.
- Understanding the genetic drivers of BC is essential for developing new therapies.
- This research offers a resource for developing novel therapeutic strategies to improve outcomes in aggressive CML.
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:43Mouse Models of Cancer Study